CheckMate 73L
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- NCT04026412 ↗
- Completed
- Bristol-Myers Squibb
- Deep
We haven't built an HCP commentary report on CheckMate 73L (nivolumab plus ipilimumab; nivolumab in previously untreated locally advanced stage III NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated from the 32 newest of 34 indexed sources (Oct 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- How immunotherapy should be timed relative to chemoradiation
- How immunotherapy and chemoradiation interact biologically
- Whether concurrent immunotherapy affects pneumonitis and other toxicity risks
Also discussed: durvalumab consolidation.
Indexed commentary on CheckMate 73L so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 22 | |
| Podcasts | 10 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- nivolumab; ipilimumab; durvalumab
- Arms
- Arm A: nivolumab + CCRT + ipilimumab · Experimental
- Arm B: nivolumab + CCRT · Experimental
- Arm C: CCRT + durvalumab · Experimental
- Enrollment
- 925
- Primary outcomes
- Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
- Sponsor
- Bristol-Myers Squibb
- Start
- Oct 8, 2019
- Primary completion
- Mar 22, 2024
- Results posted
- Yes
- Registry record
- NCT04026412 · updated Jul 24, 2025
Publications
linked from the registry- Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial. Nat Cancer. 2026 Jul;7(7):1121-1132. doi: 10.1038/s43018-026-01161-y. Epub 2026 May 13. PubMed 42129521
- De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19. PubMed 34489161